Censavudine

Censavudine

Systematic (IUPAC) name
1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
Clinical data
Legal status	Investigational
Identifiers
PubChem	CID 3008897
ChemSpider	2278330
UNII	6IE83O6NGA
ChEMBL	CHEMBL124363
NIAID ChemDB	209894
Synonyms	4'-ethynylstavudine, festinavir
Chemical data
Formula	C12H12N2O4
Molar mass	248.235 g/mol
SMILES CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
InChI InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1 Key:OSYWBJSVKUFFSU-SKDRFNHKSA-N

Censavudine (INN),^[1] is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. Censavudine is a nucleoside reverse transcriptase inhibitor that is active against HIV resistant to both abacavir and tenofovir, making the drug a candidate for people with multi-drug resistant (MDR) strains of the virus. Censavudine is a derivative of stavudine (d4T), but is less toxic. It was originally developed at Yale University.^[2]

Renaming

Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).

References

1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 110" (PDF). World Health Organization. pp. 409–410.
2. Alcorn, Keith (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.